Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19.
Körper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, Grüner B, Ernst L, Spieth P, Lepper PM, Bentz M, Zinn S, Paul G, Kalbhenn J, Dollinger MM, Rosenberger P, Kirschning T, Thiele T, Appl T, Mayer B, Schmidt M, Drosten C, Wulf H, Kruse JM, Jungwirth B, Seifried E, Schrezenmeier H; CAPSID Clinical Trial Group. Körper S, et al. Among authors: mayer b. J Clin Invest. 2021 Oct 15;131(20):e152264. doi: 10.1172/JCI152264. J Clin Invest. 2021. PMID: 34464358 Free PMC article. Clinical Trial.
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, Erdemci-Evin S, Mayer B, Hoffmann M, Pöhlmann S, Liu W, Hahn BH, Beil A, Kroschel J, Jahrsdörfer B, Schrezenmeier H, Kirchhoff F, Münch J, Müller JA. Groß R, et al. Among authors: mayer b. EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17. EBioMedicine. 2022. PMID: 34929493 Free PMC article. Clinical Trial.
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients.
Körper S, Grüner B, Zickler D, Wiesmann T, Wuchter P, Blasczyk R, Zacharowski K, Spieth P, Tonn T, Rosenberger P, Paul G, Pilch J, Schwäble J, Bakchoul T, Thiele T, Knörlein J, Dollinger MM, Krebs J, Bentz M, Corman VM, Kilalic D, Schmidtke-Schrezenmeier G, Lepper PM, Ernst L, Wulf H, Ulrich A, Weiss M, Kruse JM, Burkhardt T, Müller R, Klüter H, Schmidt M, Jahrsdörfer B, Lotfi R, Rojewski M, Appl T, Mayer B, Schnecko P, Seifried E, Schrezenmeier H. Körper S, et al. Among authors: mayer b. J Clin Invest. 2022 Dec 15;132(24):e163657. doi: 10.1172/JCI163657. J Clin Invest. 2022. PMID: 36326824 Free PMC article. Clinical Trial.
High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection.
Jacobsen EM, Fabricius D, Class M, Topfstedt F, Lorenzetti R, Janowska I, Schmidt F, Staniek J, Zernickel M, Stamminger T, Dietz AN, Zellmer A, Hecht M, Rauch P, Blum C, Ludwig C, Jahrsdörfer B, Schrezenmeier H, Heeg M, Mayer B, Seidel A, Groß R, Münch J, Kirchhoff F, Bode SFN, Strauss G, Renk H, Elling R, Stich M, Voll RE, Tönshof B, Franz AR, Henneke P, Debatin KM, Rizzi M, Janda A. Jacobsen EM, et al. Among authors: mayer b. Nat Commun. 2022 Nov 28;13(1):7315. doi: 10.1038/s41467-022-35055-1. Nat Commun. 2022. PMID: 36437276 Free PMC article.
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults.
Seidel A, Zanoni M, Groß R, Krnavek D, Erdemci-Evin S, von Maltitz P, Albers DPJ, Conzelmann C, Liu S, Weil T, Mayer B, Hoffmann M, Pöhlmann S, Beil A, Kroschel J, Kirchhoff F, Münch J, Müller JA. Seidel A, et al. Among authors: mayer b. Front Immunol. 2022 Jul 25;13:882918. doi: 10.3389/fimmu.2022.882918. eCollection 2022. Front Immunol. 2022. PMID: 35958601 Free PMC article.
1,596 results